Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.70 |
| ▸ | BRD2 | P25440 | 3/20 | 0.61 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.61 |
| ▸ | SMCHD1 | A6NHR9 | 1/20 | 0.61 |
| ▸ | MYO1G | B0I1T2 | 1/20 | 0.61 |
| ▸ | AIP | O00170 | 1/20 | 0.61 |
| ▸ | AP3B1 | O00203 | 1/20 | 0.61 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.61 |
| ▸ | CDC7 | O00311 | 1/20 | 0.61 |
| ▸ | SAP18 | O00422 | 1/20 | 0.61 |
| ▸ | KPNA3 | O00505 | 1/20 | 0.61 |
| ▸ | PPP6C | O00743 | 1/20 | 0.61 |
| ▸ | TCERG1 | O14776 | 1/20 | 0.61 |
| ▸ | UBE2L6 | O14933 | 1/20 | 0.61 |
| ▸ | PPP1R12A | O14974 | 1/20 | 0.61 |
| ▸ | U2SURP | O15042 | 1/20 | 0.61 |
| ▸ | SETD1A | O15047 | 1/20 | 0.61 |
| ▸ | ARPC1B | O15143 | 1/20 | 0.61 |
| ▸ | POLR1C | O15160 | 1/20 | 0.61 |
| ▸ | OGT | O15294 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1868413 | 0.91 | BRD4 (0.84) | BRD4BRD2BRD3SMCHD1MYO1G | |
| SCHEMBL30080573 | 0.91 | BRD4 (0.84) | BRD4BRD2BRD3SMCHD1MYO1G | |
| SCHEMBL17859088 | 0.91 | BRD4 (0.83) | BRD4BRD2BRD3SMCHD1MYO1G | |
| SCHEMBL17854817 | 0.90 | BRD4 (0.63) | BRD4BRD2BRD3EP300HDAC1 | |
| SCHEMBL12152376 | 0.88 | BRD4 (0.67) | BRD4BRD2BRD3EP300HDAC1 | |
| SCHEMBL881280 | 0.88 | BRD4 (0.67) | BRD4BRD2BRD3EP300HDAC1 | |
| SCHEMBL17859089 | 0.87 | BRD4 (0.73) | BRD4BRD2BRD3SMCHD1MYO1G | |
| SCHEMBL19068594 | 0.86 | BRD4 (0.71) | BRD4BRD2BRD3SMCHD1MYO1G | |
| SCHEMBL20841295 | 0.86 | BRD4 (0.85) | BRD4BRD2BRD3SMCHD1MYO1G | |
| SCHEMBL17859090 | 0.86 | BRD4 (0.72) | BRD4BRD2BRD3SMCHD1MYO1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200317635-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-10669253-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10464925-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10239888-B2 | Targeted protein degradation using a mutant E3 ubiquitin ligase | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20190071415-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071415-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | BRD4 687/4885BRD2 529/4885BRD3 705/4885 |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, XIAP, MDM2 | BRD4 1005/4885BRD2 881/4885BRD3 951/4885 |
| US-10239888-B2 | Targeted protein degradation using a mutant E3 ubiquitin ligase | CRBN, MDM2, CBL | BRD4 2473/4885BRD2 1866/4885BRD3 2067/4885 |
| US-10464925-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | BRD4 687/4885BRD2 529/4885BRD3 705/4885 |
| US-10669253-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, SMARCE1, MDM2 | BRD4 340/4885BRD2 149/4885BRD3 272/4885 |
| US-20200317635-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | BRD4 687/4885BRD2 529/4885BRD3 705/4885 |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | BRD4 687/4885BRD2 529/4885BRD3 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.